Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
Korro Bio, Inc. (KRRO)
Company Research
Source: GlobeNewswire
-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110 -First participant dosing anticipated in the first quarter of 2025 -Interim readout expected in second half of 2025 and completion of Phase 1/2a study anticipated in 2026 CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that it has received approval from the Australian Bellberry Human Research Ethics Committee (HREC) and clearance from the Australian Therapeutic Goods Administration (TGA) to initiate a Phase 1/2a clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD). “We are thrilled to receive approval to proceed with our clinical study in Australia,” said Kemi Olugemo, MD, Chief Medical Officer at Korro. “Multiple d
Show less
Read more
Impact Snapshot
Event Time:
KRRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRRO alerts
High impacting Korro Bio, Inc. news events
Weekly update
A roundup of the hottest topics
KRRO
News
- Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.MarketBeat
- Korro to Participate in Upcoming Investor ConferencesGlobeNewswire
- Korro to Present at the Jefferies London Healthcare ConferenceGlobeNewswire
- Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.MarketBeat
- Korro Bio, Inc. (NASDAQ: KRRO) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
KRRO
Earnings
- 11/12/24 - Beat
KRRO
Sec Filings
- 12/10/24 - Form 424B3
- 12/10/24 - Form 424B3
- 12/10/24 - Form EFFECT
- KRRO's page on the SEC website